Improving agreement in assessment of synovitis in rheumatoid arthritis
Peter Cheung(Délégation Paris 5), Laure Gossec(Inserm), Nathalie Balandraud, Gaël Mouterde(Hôpital Lapeyronie), Ghislaine Gill(Centre Hospitalier Régional et Universitaire de Nancy), Gérard Chalès(Inserm), Martin Soubrier(Centre Hospitalier Universitaire de Clermont-Ferrand), Isabelle Chary-Valckenaere(Centre National de la Recherche Scientifique), F. Pouyol(Centre Hospitalier Universitaire de Lille), Emmanuelle Dernis(Centre Hospitalier du Mans), Sandrine Guis(Centre National de la Recherche Scientifique), Emmanuel Chatelus(Laboratoire National de Référence), Pascal Richette(Inserm), Maxime Dougados(Inserm), Stéphan Pavy(Hôpitaux Universitaires Paris-Ouest), Mélanie Gilson(Centre Hospitalier Universitaire de Grenoble), Thierry Marhadour(Centre Hospitalier Régional Universitaire de Brest), André Vincent(Centre Hospitalier du Mans), Adeline Ruyssen‐Witrand(Centre Hospitalier Universitaire de Toulouse)
Cited by 16
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
|Annals of the Rheumatic Diseases|2017|1.6k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis
|Arthritis & Rheumatism|2002|574
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538